Mini Review

Avicenna Journal of Medical Biotechnology
Volume 17, Issue 4, 242-248
https://doi.org/10.18502/ajmb.v17i4.20070

Check for updates

Challenges and Future Prospects of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Nanomedicine: A Focus on Toxicity, Imaging, and Theranostics

Maryam Alvandi [1,2], Sahar Nosrati [3], Ramin Mansouri [4], Zahra Shaghaghi [5*], Shahnaz Saednia [6], Sara Alipour [4] and Farzad Fathi [4]

1. Cardiovascular Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
2. Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
3. Institute of Nuclear Chemistry and Technology, Dorodna 16 Str, 03-195, Warsaw, Poland
4. Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
5. Cancer Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
6. Farabi Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

*** Corresponding author:**
Zahra Shaghaghi, Ph.D.,
Cancer Research Center, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
Tel: +98 81 38381737
Fax: +98 81 38381686
E-mail:
z.shaghaghi90@yahoo.com,
z.shaghaghi@umsha.ac.ir
Received: 24 Dec 2024
Accepted: 9 Jul 2025

Abstract

Superparamagnetic Iron Oxide Nanoparticles (SPIONs) have emerged as a pivotal tool in nanomedicine, offering potential in drug delivery, imaging, and targeted therapies. However, their application is challenged by issues such as cytotoxicity, uneven biodistribution, and biocompatibility. SPIONs are predominantly cleared through renal or hepatobiliary pathways, with size and charge playing critical roles in determining their fate. While smaller SPIONs optimize renal clearance, their propensity to agglomerate and activate macrophages may induce inflammatory responses. Radiolabeled SPIONs face additional challenges in molecular imaging and nuclear medicine. Emerging strategies, such as chelator-free radiolabeling and multi-component nanoparticles, aim to address these limitations by improving targeting specificity and enhancing biocompatibility. Looking forward, SPIONs hold immense potential in theranostics, particularly in integrating imaging with targeted drug delivery and therapies. Advances in synthesis and surface functionalization may enhance their safety and effectiveness. Future research should focus on optimizing SPIONs, integrating them with therapeutic agents, and improving targeting and clearance mechanisms. Collaboration among experts and the use of *Artificial Intelligence (AI)* modeling could accelerate their development for personalized treatment applications. This review uniquely highlights recent advances in radiolabeled SPIONs for molecular imaging and targeted therapy, addressing challenges like biocompatibility, stability, and translational applicability.

Keywords: Molecular imaging, PET/MRI, Radiolabeling, Superparamagnetic iron oxide nanoparticles, Toxicity
To cite this article: Alvandi M, Nosrati S, Mansouri R, Shaghaghi Z, Saednia Sh, Alipour S, et al. Challenges and Future Prospects of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Nanomedicine: A Focus on Toxicity, Imaging, and Theranostics. Avicenna J Med Biotech 2025; 17(4):242-248.

Introduction

Cancer remains a major challenge in medicine, accounting for a significant portion of global mortality [1]. A crucial factor in addressing cancer effectively is early and precise diagnosis [2]. Nanotechnology has emerged as a transformative tool in cancer management, offering advanced capabilities for early detection, precise identification, and personalized therapy [3,4]. Among the most promising nanomaterials, Superparamagnetic Iron Oxide Nanoparticles (SPIONs) have gained considerable attention for their applications in diagnosis and therapy. These particles, typically composed of γ-Fe_2O_3 (maghemite) or Fe_3O_4 (magnetite), have been investigated as Magnetic Resonance Imag-ing (MRI) contrast agents, drug carriers, and mediators of hyperthermia. Current research on SPIONs is expanding their potential applications in diagnostic imaging as well as in targeted drug delivery systems. The integration of anticancer drugs with functionalized SPIONs

Copyright © 2025, Avicenna Journal of Medical Biotechnology

This work is licensed under a Creative Commons Attribution–NonCommercial 4.0 International License.

for site-specific therapy is a rapidly advancing field in cancer treatment. Radiolabeling extends their utility to *Positron Emission Tomography (PET)* and Single-Photon Emission Computed Tomography (SPECT), enabling sensitive whole-body molecular imaging with anatomical MRI precision [5,6]. The clinical translation of radiolabeled SPIONs faces several challenges, including standardization of synthesis protocols, immunogenicity, and potential long-term toxicity. Unlike prior reviews that separately examine SPIONs or radiolabeled nanoparticles, this work provides an integrated perspective on radiolabeled SPIONs, assessing their synthesis strategies, surface modifications, biological interactions, and the translational barriers to clinical implementation in cancer theranostics.

Advances in functionalized MNPs for cancer therapy

Functionalized MNPs (Magnetic nanoparticles) are gaining traction for cancer therapeutics, with many in preclinical and early clinical development [7,8]. Multifunctional MNPs have been engineered for targeted delivery of therapeutic agents such as small molecules and miRNAs, effectively addressing chemoresistance in cancer cells [9]. For instance: *Composite Nanoparticles:* Magnetic iron oxide (Fe_3O_4) nanoparticles functionalized with β-cyclodextrin crosslinked with ethylenediaminetetraacetic acid (EDTA) or trastuzumab have shown excellent cellular uptake, tumor targeting, and therapeutic outcomes, including reduced cancer cell viability, apoptosis induction, and inhibition of proliferation in *in vitro* cancer models [10]. *SPION Functionalization*: SPIONs with cores of Fe_3O_4, γ-Fe_2O_3, or other materials like nickel and cobalt have been modified with hydrophilic organic polymers [*e.g.*, polysaccharides, dextran, Polyethylene Glycol (PEG), Polyvinyl Alcohol (PVA)] or targeting ligands (*e.g.*, avidin, biotin, carboxyl groups). These modifications enhance biocompatibility, bio-distribution, and therapeutic efficacy by shielding the nanoparticles from biological degradation and improving their interaction with cancer tissues [7]. The surface characteristics and oxidation state of SPIONs significantly influence their morphology, surface charge, and behavior in biological systems. For instance, surface charge impacts opsonization, a process where plasma proteins and biomolecules adhere to the nanoparticle surface, forming a protein corona that facilitates phagocytosis by macrophages. Studies have shown that smaller nanoparticle sizes and increased hydrophobicity can reduce opsonization, thereby improving circulation time [11]. SPIONs' surface properties, are such as crystallinity, roughness, and hydrophilicity, also play a crucial role in their *in vivo* applications, determining factors like blood circulation half-life and overall efficacy. These properties dictate the choice of coating materials, which may bond to the SPION surface through physical interactions or direct chemical binding.

A wide variety of materials are used to coat SPIONs, including: Polymers: PEG, Polylactic Acid (PLA), chitosan, dextran, and poly (lactic-co-glycolic acid) (PLGA); Biological molecules: Human serum albumin, mannose, alginate, and heparin; other functional coatings: Liposomes, arabinogalactan, and Polyethylene Imine (PEI). Coating materials such as PEG and dextran help prevent opsonization, reduce uptake by macrophages and the Reticuloendothelial System (RES), and mitigate aggregation. Conversely, uncoated SPIONs with hydrophobic surfaces exhibit rapid uptake by macrophages and accumulation in RES organs such as the liver, spleen, and lymph nodes [12,13]. Additionally, coating SPIONs with liposomes can prevent aggregation and facilitate tumor cell targeting. These coatings enhance the blood half-life, colloidal stability, biocompatibility, and water solubility of SPIONs. They also improve accumulation at tumor sites *via* the Enhanced Permeability and Retention (EPR) effect, making them ideal for imaging and therapeutic applications. Furthermore, bio conjugation of biological moieties on SPION surfaces enables functional imaging modalities and theranostic applications [12,13].

Old-school ways of tagging SPIONs with radioactive markers usually leaned on chelators like Dodecane Tetraacetic Acid (DOTA) and Diethylenetriaminepentaacetic Acid (DTPA). But lately, new tricks skipping the chelators altogether have stepped up the game—boosting stability, cutting down on stray effects, and making them stick around longer in the body. By tapping into SPIONs' built-in knack for grabbing metals, scientists can now slap radionuclides like ^{68}Ga straight onto them. This tweak sharpens up how they move through the body and amps up imaging precision, raising the bar for early-stage lab models [14].

SPION characteristics and superparamagnetic properties

SPIONs are widely used in theranostics due to their unique physical and magnetic properties. Key characteristics that enable their biomedical applications include:

Size control: SPIONs range from 1–100 *nm*, making them comparable in size to biological entities such as cells (10–100 *μm*), viruses (20–450 *nm*), proteins (5–50 *nm*), and genes (2 *nm* wide, 10–100 *nm* long). Their size can be precisely tuned for specific applications [15,16]. For intravenous applications, SPIONs with diameters between 10 and 100 *nm* are ideal; particles smaller than 10 *nm* or larger than 200 *nm* are rapidly cleared by the RES [17,18].

Superparamagnetic properties: SPIONs exhibit superparamagnetism, becoming magnetized only in the presence of an external magnetic field and rapidly losing magnetization once the field is removed. This property allows, precise control and localization of SPIONs in specific body regions under a magnetic field. Prevention of aggregation and embolization in capillary vessels during *in vivo* applications. Use in diverse applications such as molecular labeling, bio sensing, biomolecule separation, and targeted drug and gene delivery [19,20].

Table 1. Comparison of imaging modalities used with radiolabeled SPIONs

Imaging modality	Advantages	Limitations	Clinical examples
MRI	High spatial resolution, no radiation	Low sensitivity	Ferumoxytol-enhanced MRI for tumor detection
PET	High sensitivity and quantification	Radiation exposure, cost	^{64}Cu-labeled SPIONs for cancer imaging
SPECT	Widespread availability, cost-effective	Lower resolution than PET	^{99m}Tc-labeled SPIONs in lymph node imaging

Localized heating for hyperthermia therapy: SPIONs can generate localized heat (45-47°C) when exposed to an alternating magnetic field, making them useful for hyperthermia therapy to selectively kill cancer cells.

Magnetic susceptibility: SPIONs' Superparamagnetic properties enhance magnetic susceptibility, which diphase protons in external magnetic fields. This makes SPIONs highly effective as contrast agents in MRI [15,21].

SPION synthesis

SPIONs have gained significant attention as contrast agents in MRI due to their ability to alter nuclear spin relaxation of water protons, enhancing the visibility of target regions by creating darkened contrast areas. These nanoparticles offer several advantages, including cost effectiveness, biodegradability, chemical stability, low toxicity, and tunable properties such as size, surface chemistry, and diffusion capacity. These attributes influence their biodistribution, metabolic pathways, and stability in biological systems [3,11,22]. SPIONs are utilized in multimodal imaging for applications such as cell targeting, drug delivery, disease diagnosis, and treatment monitoring, potentially reducing imaging sessions and improving diagnostic efficiency. Some SPION formulations, such as Ferridex I.V® (for liver and spleen imaging) and Combidex® (for lymph node metastasis imaging), have been clinically approved [23,24].

Targeted SPIONs have shown promise as MRI contrast agents for detecting

Overexpressed receptors on tumor cell surfaces, abnormal angiogenesis in the tumor microenvironment, Circulating Tumor Cells (CTCs) and soluble tumor markers [18,25,26]. However, SPIONs lack inherent radioactive properties essential for PET. To overcome this, SPIONs have been radiolabeled with isotopes such as ^{99m}Tc, ^{125}I, ^{111}In, ^{131}I, ^{18}F, ^{11}C, ^{67,68}Ga, ^{64}Cu, and ^{124}I. These radiolabeled SPIONs can be used in hybrid imaging techniques such as PET/MRI and SPECT/MRI, improving early detection, multimodal imaging, and theranostic capabilities [27,28]. SPION synthesis can involve physical and biological methods, though these approaches face challenges such as scaling up production and achieving well-defined structures with consistent size distributions.

Major issues in SPION synthesis include

Achieving mono-disparity to prevent aggregation and continuous nanoparticle growth caused by magnetic interactions and surface energy, controlling size, shape, and composition, optimizing magnetic properties for biomedical applications [13,26].

Imaging properties of SPIONs

Noninvasive imaging techniques are increasingly recognized for their ability to provide early diagnosis, whole-body coverage, and repeated assessments, surpassing the limitations of invasive biopsy techniques. While techniques like SPECT and PET are valuable, MRI remains the gold standard for noninvasive diagnostic imaging due to its high spatial resolution and detailed anatomical information (Table 1) [29]. MRI contrast is categorized into T1-weighted (longitudinal relaxation) and T2-weighted (transverse relaxation) images, based on the relaxation processes involved [30]. To achieve high-resolution molecular imaging using MRI, several factors must be addressed: Access to high-affinity probes with favorable pharmacodynamics. Probes capable of overcoming biological delivery barriers such as cell membranes, interstitial spaces, and vascular walls. Utilization of advanced biological or chemical strategies to enhance probe delivery and retention [31,32]. MRI sensitivity relies on the relaxivity values of contrast agents. SPIONs are particularly effective as MRI contrast agents because they have high r2 relaxivities, which can exceed 200 $mM^{-1}s^{-1}$. This characteristic makes them especially suitable for T2-weighted imaging. In contrast, commercial T1 contrast agents consist of paramagnetic complexes made from transition or lanthanide metals, such as Gd^{3+} and Mn^{2+}. However, these T1 agents often exhibit low sensitivity for specific imaging applications. As a result, significant research has been conducted into alternatives like SPIONs, which are clinically approved as T2 contrast agents for disease detection when used in conjunction with an external magnetic field [33]. Relaxivity measurements also correlate with SPION accumulation in tumors, providing valuable diagnostic insights [34,35]. The mechanism involves SPIONs interacting with surrounding water molecules to increase the relaxation rates of water protons. After exposure to a Radiofrequency (RF) pulse, protons return to equilibrium *via* longitudinal (T1) and transverse (T2) relaxation. SPIONs' superparamagnetic properties enhance the dephasing of water protons, which contributes to the contrast in MRI [36-38]. SPIONs are primarily used as negative (T2) contrast agents in MRI due to their high magnetic susceptibility. However, smaller SPIONs have also demonstrated potential as positive (T1) contrast agents, further expanding their applications (Figure 1).

Toxicity and modification of SPIONs

The use of SPIONs in biomedical applications raises safety concerns, particularly regarding their cytotoxic



Figure 1. Schematic figure to visually organize the discussed challenges and proposed strategies.

potential. This toxicity often stems from oxidative stress triggered by the release of free iron ions (Fe^{2+}) during SPION degradation within acidic cellular environments. Following phagocytosis and subsequent lysosomal degradation, free Fe^{2+} is released, which can catalyze the production of Reactive Oxygen Species (ROS) through the Fenton reaction. Elevated ROS levels can result in DNA damage, lipid peroxidation, and inflammatory responses, compromising cellular integrity [39,40]. Under normal physiological conditions, ROS production is regulated by antioxidant systems such as Glutathione (GSH) and antioxidant enzymes. However, when oxidative stress overwhelms these systems, cells may experience cytotoxic effects mediated by signaling pathways like the Mitogen-Activated Protein Kinase (MAPK) and nuclear factor-kB (NF-κB) cascades. Low oxidative stress levels activate nuclear factor erythroid 2–related factor 2 (Nrf2), which promotes the expression of antioxidant and detoxification enzymes. In contrast, higher oxidative stress levels can exacerbate inflammation and cellular damage [41].

Cells manage iron homeostasis through proteins such as Divalent Metal Transporter 1 (DMT1), which imports iron, transferrin receptor (CD71), which facilitates transferrin-mediated iron uptake, and ferritin, which sequesters iron to prevent free radical formation. Iron export is regulated by ferroportin (FPN) and ZRT/IRE-like proteins. However, SPION degradation bypasses these regulatory mechanisms by releasing iron directly into the labile iron pool, potentially overloading these systems [42,43]. To evaluate SPION-induced cytotoxicity, researchers measure biomarkers of oxidative stress, including lipid peroxidation, reduced glutathione, and antioxidant enzyme activity (*e.g.*, catalase, glutathione peroxidase, and superoxide dismutase). Studies have shown that free iron from SPION degradation is the primary contributor to oxidative stress. Using iron chelators has been effective in mitigating ROS generation, Lactate Dehydrogenase (LDH) release, and DNA damage [44,45]. Additionally, macrophage type influences SPION toxicity, with mouse alveolar macrophages exhibiting lower oxidative activity compared to peritoneal macrophages [44-46].

Unique size and shape-dependent toxicity

The small size and high surface area of SPIONs can amplify cytotoxic effects. Smaller SPIONs exhibit increased reactivity and cytotoxicity per unit mass compared to larger nanoparticles. However, nanoparticle shape also plays a role; for example, rod-shaped SPIONs have demonstrated greater toxicity than spherical ones, despite their smaller surface area. These variations suggest that factors beyond surface area, such as surface charge, composition, and shape, influence SPION toxicity [47,48]. The pH of the surrounding environment and SPION surface properties, such as coatings and charge, also affect their cytotoxicity and biological interactions. For instance, uncoated SPIONs have been shown to decrease cell viability and increase ROS production in human fibroblasts at concentrations as low as 2 $\mu g/cm^2$, with higher concentrations causing DNA damage [49-51]. Surface modifications can mitigate these effects by altering SPION interactions with cells and proteins. By tailoring SPION size, charge, and surface coatings, researchers can reduce phagocytosis and protein adsorption, which influence clearance, biodistribution, and cytotoxicity. When SPIONs bind to serum proteins or form complexes with other biomolecules, their hydrodynamic size increases, reducing renal clearance and extending their circulation time. These complexes may also enhance tissue penetration and intracellular uptake, potentially leading to unintended cytotoxic effects [49,51]. To minimize toxicity, strategies such as functionalizing SPION surfaces with biocompatible coatings or modifying their physicochemical properties have been employed. These approaches reduce ROS generation, protein adsorption, and oxidative damage, improving the safety profile of SPIONs for biomedical applications.

Site-specific accumulation

SPIONs are primarily excreted through either the renal or hepatobiliary pathways. Due to the potential for greater cytotoxicity from intracellular enzymatic modification in the hepatobiliary system, the renal pathway is generally preferred to minimize toxicity [51]. For SPIONs to be excreted *via* the renal system, they must be small enough to pass through the glomerular filtration barrier, which has a physiological pore size of about 4.5-5 *nm* in diameter. Particles smaller than 4.5 *nm* can easily pass through, while particles ranging from 6–8 *nm*, especially if cationic, may still pass through these pores [52]. However, caution is needed, as overly cationic or anionic particles can increase Hydrodynamic Diameter (HD) due to charge-induced adsorption by serum proteins [53]. SPIONs do not distribute evenly throughout the body and tend to accumulate preferentially in certain organs. For optimal blood circulation during imaging, SPIONs should be sized between 10 *nm* and 200 *nm*. This size range helps avoid rapid clearance by the kidneys and prevents sequestration in the spleen [54]. However, this size range can com-

plicate the even distribution of SPIONs and potentially lead to toxicity. Due to their small size and large surface area, SPIONs tend to agglomerate before being phagocytized by macrophages in the liver (Kupffer cells) and other cells of the RES. This phagocytosis activates macrophages, triggering an inflammatory response that can involve the recruitment of various immune cells and the generation of ROS to destroy the foreign particles. Macrophages, once activated, may migrate throughout the body and differentiate into specific types such as Kupffer cells in the liver, osteoclasts in bone, microglia in the brain, alveolar macrophages in the lungs, and mesangial cells in the kidneys [55].

Tumor imaging and the growing potential of SPIONs

SPIONs are shaping up to be a real game-changer for spotting tumors in MRI scans. Lately, researchers have been digging into ultrafine SPIONs, which sneak into tumors more effectively by riding the wave of something called the EPR effect—basically, taking advantage of leaky tumor blood vessels. They've been a big help in imaging the liver and spleen, making it easier to tell apart different kinds of lesions. Sure, some SPION-based contrast agents got pulled off the shelves because they struggled to pick out liver lesions clearly, but they're still a solid pick for folks with kidney issues. When it comes to brain tumors, SPIONs shine by helping measure blood volume in the region, giving doctors a clearer picture. Cancer's a huge focus—understandably, given how much it matters worldwide—but SPIONs aren't just a one-trick pony. Their strengths could stretch into all sorts of medical areas, opening up a ton of possibilities [56]. Clinical studies have shown that ferumoxytol-boosted MRI is an ace at finding metastatic lymph nodes, hitting sensitivity rates over 90%, way better than the usual contrast agents. Plus, early Phase I trials testing SPIONs for magnetic hyperthermia—where they heat up to zap tumors—look promising for shrinking glioblastoma and prostate cancer. And then there's the latest combo trick: pairing radiolabeled SPIONs with dual PET/MRI imaging, which is sharpening up diagnostics for heart conditions and cancer alike. On top of that, these magnetic nanoparticles are easy to tweak, which makes them perfect for cooking up blends that work across multiple imaging styles—like CT, PET/SPECT, ultrasound, fluoroscopy, or even photoacoustic imaging.

Challenges and functionalization

Despite their advantages, SPIONs face challenges like agglomeration and low affinity for biomolecules.

Agglomeration: This can lead to loss of functionality and *in vivo* complications. Coating SPIONs with biocompatible materials solves this issue, improving colloidal stability.

Low Affinity for Biomolecules: Functionalizing SPION coatings with specific ligands and biological molecules enhances their affinity for targeted biomolecules and therapeutic agents [57,58].

Imaging issues: One big roadblock stopping SPIONs from hitting the clinic is that making and tweaking them isn't always consistent. Differences in how they're cooked up can mess with their physical and chemical traits, which in turn throws off how well they work for imaging. To sort this out, regulatory folks and nanomedicine groups are teaming up to set some ground rules—think standard playbooks for controlling their size spread, surface charge, and stability checks [59]. By addressing these challenges, SPIONs continue to hold promise for advancing theranostics, particularly in imaging, targeted drug delivery, and cancer therapy.

Conclusion

SPIONs have significant potential in nanomedicine for imaging and targeted drug delivery. However, issues like cytotoxicity, uneven distribution, and safety concerns limit their clinical use. Advances in synthesis and functionalization aim to improve their biocompatibility and efficacy. By integrating SPIONs with therapeutic agents, localized treatments with fewer side effects could be achieved. Ongoing research is focused on addressing these challenges, refining SPION designs, and utilizing AI to optimize their medical applications.

Acknowledgement

The authors would like to thank the Clinical Research Development Unit of Farshchian Heart Hospital, Hamadan University of Medical Sciences, Hamadan, Iran, for their assistance throughout the period of study.

Funding: None.

Conflict of Interest

Authors declare no conflict of interest.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-49.
2. Bakhtiary Z, Saei AA, Hajipour MJ, Raoufi M, Vermesh O, Mahmoudi M. Targeted superparamagnetic iron oxide nanoparticles for early detection of cancer: Possibilities and challenges. Nanomedicine 2016;12(2):287-307.
3. Farzin L, Sheibani S, Moassesi ME, Shamsipur M. An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions. J Biomed Mater Res A 2019;107(1):251-85.
4. Ma YY, Jin KT, Wang SB, Wang HJ, Tong XM, Huang DS, et al. Molecular imaging of cancer with nanoparticle-based theranostic probes. Contrast Media Mol Imaging 2017;2017(1):1026270.
5. Alvandi M, Shaghaghi Z, Aryafar V, Fariba F, Sanaei Z. The evaluation of left ventricular dyssynchrony in hy-

pertensive patients with a preserved systolic function undergoing gated SPECT myocardial perfusion imaging. Ann Nucl Med 2019;33(12):899-906.

6. Shaghaghi Z, Mansouri R, Nosrati S, Alvandi M. Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET. Future Oncol 2025;21(18):2367-83.
7. Mukherjee S, Liang L, Veiseh O. Recent advancements of magnetic nanomaterials in cancer therapy. Pharmaceutics 2020;12(2):147.
8. Racca L, Cauda V. Remotely activated nanoparticles for anticancer therapy. Nanomicro Lett 2021;13:11.
9. Naz S, Shamoon M, Wang R, Zhang L, Zhou J, Chen J. Advances in therapeutic implications of inorganic drug delivery nano-platforms for cancer. Int J Mol Sci 2019; 20(4):965.
10. Wenzel D. Magnetic nanoparticles: novel options for vascular repair? Nanomedicine (Lond) 2016 Apr;11(8): 869-72.
11. Garcia J, Tang T, Louie AY. Nanoparticle-based multimodal PET/MRI probes. Nanomedicine (Lond) 2015;10 (8):1343-59.
12. Aziz OAA, Arafa K, Dena ASA, El-Sherbiny IM. Superparamagnetic iron oxide nanoparticles (SPIONs): preparation and recent applications. J Nanotech Adv Mat 2020;8:21-9.
13. Li L, Jiang W, Luo K, Song H, Lan F, Wu Y, et al. Superparamagnetic iron oxide nanoparticles as MRI contrast agents for non-invasive stem cell labeling and tracking. Theranostics 2013;3(8):595-615.
14. Stockhofe K, Gimnich M, Klinker K, Roesch F, Barz M, Ross TL. Radiolabeling of cross-linked polymer micelles with 68Ga for PET-imaging. Society of Nuclear Medicine; 2016.
15. Adamiano A, Iafisco M, Sandri M, Basini M, Arosio P, Canu T, et al. On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging. Acta Biomater 2018;73:458-69.
16. Psimadas D, Baldi G, Ravagli C, Bouziotis P, Xanthopoulos S, Franchini MC, et al. Preliminary evaluation of a 99mTc labeled hybrid nanoparticle bearing a cobalt ferrite core: in vivo biodistribution. J Biomed Nanotechnol 2012;8(4):575-85.
17. Ansari MO, Ahmad MF, Shadab G, Siddique HR. Superparamagnetic iron oxide nanoparticles based cancer theranostics: A double edge sword to fight against cancer. Journal of Drug Delivery Science and Technology 2018;45:177-83.
18. Singh N, Jenkins GJ, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev 2010;1(1):5358.
19. Lamichhane N, Sharifabad ME, Hodgson B, Mercer T, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs) as therapeutic and diagnostic agents. Nanoparticle therapeutics: Elsevier; 2022. p. 455-97.
20. Zhang L, Jin R, Sun R, Du L, Liu L, Zhang K, et al. Superparamagnetic iron oxide nanoparticles as magnetic resonance imaging contrast agents and induced autophage response endothelial progenitor cells. J Biomed Nanotechnol 2019 Feb 1;15(2):396-404.
21. Sodipo BK, Aziz AA. Recent advances in synthesis and surface modification of superparamagnetic iron oxide nanoparticles with silica. Journal of Magnetism and Magnetic Materials 2016;416:275-91.
22. de Souza Albernaz M, Toma SH, Clanton J, Araki K, Santos-Oliveira R. Decorated superparamagnetic iron oxide nanoparticles with monoclonal antibody and diethylene-triamine-pentaacetic acid labeled with thechnetium-99m and galium-68 for breast cancer imaging. Pharm Res 2018;35(1):24.
23. Goel S, England CG, Chen F, Cai W. Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics. Adv Drug Deliv Rev 2017;113:157-76.
24. Shanehsazzadeh S, Grüttner C, Yousefnia H, Lahooti A, Gholami A, Nosrati S, et al. Development of 177Lu-DTPA-SPIO conjugates for potential use as a dual contrast SPECT/MRI imaging agent. Radiochimica Acta 2016;104(5):337-44.
25. Polo E, del Pino P, Pardo A, Taboada P, Pelaz B. Magnetic nanoparticles for cancer therapy and bioimaging. InNanooncology: Engineering nanomaterials for cancer therapy and diagnosis 2018 Jun 2 (pp. 239-279). Cham: Springer International Publishing.
26. Wu W, Wu Z, Yu T, Jiang C, Kim WS. Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mater 2015;16(2):023501.
27. Ittrich H, Peldschus K, Raabe N, Kaul M, Adam G, editors. Superparamagnetic iron oxide nanoparticles in biomedicine: applications and developments in diagnostics and therapy. Rofo 2013 Dec;185(12):1149-66.
28. Madru R, Svenmarker P, Ingvar C, Ståhlberg F, Engels SA, Knutsson L, et al. Development of a hybrid nanoprobe for triple-modality MR/SPECT/optical fluorescence imaging. Diagnostics (Basel) 2014;4(1):13-26.
29. Wang G, Xie H, Hou S, Chen W, Yang X. Development of high-field permanent magnetic circuits for NMRI/MRI and imaging on mice. Biomed Res Int 2016;2016(1): 8659298.
30. Javed Y, Akhtar K, Anwar H, Jamil Y. MRI based on iron oxide nanoparticles contrast agents: effect of oxidation state and architecture. Journal of Nanoparticle Research 2017;19:366.
31. Huang J, Zhong X, Wang L, Yang L, Mao H. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics 2012;2(1):86-102.
32. Lurie DJ. Basic MRI physics for radiotherapy physicists. Physica Medica 2016;32:175.
33. Si G, Du Y, Tang P, Ma G, Jia Z, Zhou X, et al. Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI. Natl Sci Rev 2024;11(5):nwae057.
34. Eghbali P, Fattahi H, Laurent S, Muller RN, Oskoei YM. Fluorophore-tagged superparamagnetic iron oxide nano-

particles as bimodal contrast agents for MR/optical imaging. Journal of the Iranian Chemical Society 2016;13:87-93.

35. Huang J, Qian W, Wang L, Wu H, Zhou H, Wang AY, et al. Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer. Int J Nanomedicine 2016:3087-99.
36. Amiri H, Saeidi K, Borhani P, Manafirad A, Ghavami M, Zerbi V. Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents. ACS Chem Neurosci 2013;4(11):1417-29.
37. Frantellizzi V, Conte M, Pontico M, Pani A, Pani R, De Vincentis G. New frontiers in molecular imaging with superparamagnetic iron oxide nanoparticles (SPIONs): efficacy, toxicity, and future applications. Nucl Med Mol Imaging 2020;54:65-80.
38. Wang Y, Ye F, Jeong EK, Sun Y, Parker DL, Lu ZR. Noninvasive visualization of pharmacokinetics, biodistribution and tumor targeting of poly [N-(2-hydroxypropyl) methacrylamide] in mice using contrast enhanced MRI. Pharmaceutical Research 2007;24:1208-16.
39. Donaldson K, Schinwald A, Murphy F, Cho WS, Duffin R, Tran L, et al. The biologically effective dose in inhalation nanotoxicology. Acc Chem Res 2013;46(3):723-32.
40. Galaris D, Pantopoulos K. Oxidative stress and iron homeostasis: mechanistic and health aspects. Crit Rev Clin Lab Sci 2008;45(1):1-23.
41. Halliwell B, Gutteridge JM. Free radicals in biology and medicine: Oxford university press; 2015.
42. Collard KJ. Iron homeostasis in the neonate. Pediatrics 2009;123(4):1208-16.
43. Kornberg TG, Stueckle TA, Antonini JM, Rojanasakul Y, Castranova V, Yang Y, et al. Potential toxicity and underlying mechanisms associated with pulmonary exposure to iron oxide nanoparticles: conflicting literature and unclear risk. Nanomaterials 2017;7(10):307.
44. Malvindi MA, De Matteis V, Galeone A, Brunetti V, Anyfantis GC, Athanassiou A, et al. Toxicity assessment of silica coated iron oxide nanoparticles and biocompatibility improvement by surface engineering. PloS One 2014;9(1):e85835.
45. Reddy UA, Prabhakar P, Mahboob M. Biomarkers of oxidative stress for in vivo assessment of toxicological effects of iron oxide nanoparticles. Saudi J Biol Sci 2017;24(6):1172-80.
46. Park EJ, Umh HN, Choi DH, Cho MH, Choi W, Kim SW, et al. Magnetite-and maghemite-induced different toxicity in murine alveolar macrophage cells. Arch Toxicol 2014;88:1607-18.
47. Lee JH, Ju JE, Kim BI, Pak PJ, Choi EK, Lee HS, et al. Rod-shaped iron oxide nanoparticles are more toxic than sphere-shaped nanoparticles to murine macrophage cells. Environ Toxicol Chem 2014;33(12):2759-66.
48. Shaghaghi Z, Nosrati S, Mansouri R, Alvandi M. Advances and Challenges in the Application of Radiolabeled Magnetic Nanoparticles for Cancer Theranostics. Nucl Med Mol Imaging 2025;59(5):315-28.
49. Bhattacharya K, Davoren M, Boertz J, Schins RP, Hoffmann E, Dopp E. Titanium dioxide nanoparticles induce oxidative stress and DNA-adduct formation but not DNA-breakage in human lung cells. Part Fibre Toxicol 2009;6:1-11.
50. Chen Z, Yin JJ, Zhou YT, Zhang Y, Song L, Song M, et al. Dual enzyme-like activities of iron oxide nanoparticles and their implication for diminishing cytotoxicity. ACS Nano 2012;6(5):4001-12.
51. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008; 3(5):703-17.
52. Nelson NR, Port JD, Pandey MK. Use of superparamagnetic iron oxide nanoparticles (SPIONs) via multiple imaging modalities and modifications to reduce cytotoxicity: An educational review. Journal of Nanotheranostics 2020;1(1):105-35.
53. Soo Choi H, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol 2007;25(10):1165-70.
54. Stolnik S, Illum L, Davis S. Long circulating microparticulate drug carriers. Advanced Drug Delivery Reviews 2012;64:290-301.
55. Mirshafiee V, Sun B, Chang CH, Liao YP, Jiang W, Jiang J, et al. Toxicological Profiling of Metal Oxide Nanoparticles in Liver Context Reveals Pyroptosis in Kupffer Cells and Macrophages versus Apoptosis in Hepatocytes. ACS Nano 2018 Apr 24;12(4):3836-3852.
56. Lapusan R, Borlan R, Focsan M. Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials. Nanoscale Adv Apr 2;6(9):2234-59.
57. Azadbakht B, Afarideh H, Ghannadi-Maragheh M, Bahrami-Samani A, Asgari M. Preparation and evaluation of APTES-PEG coated iron oxide nanoparticles conjugated to rhenium-188 labeled rituximab. Nucl Med Biol 2017;48:26-30.
58. Hajiramezanali M, Atyabi F, Mosayebnia M, Akhlaghi M, Geramifar P, Jalilian AR, et al. 68Ga-radiolabeled bombesin-conjugated to trimethyl chitosan-coated superparamagnetic nanoparticles for molecular imaging: preparation, characterization and biological evaluation. Int J Nanomedicine 2019:2591-605.
59. García-Fernández J, de la Fuente Freire M. Exosome-like systems: nanotechnology to overcome challenges for targeted cancer therapies. Cancer Lett 2023;561:216151.